沙巴棕辅助治疗对良性前列腺增生患者EGF和PGE2的影响

Clinical efficacy of Sabale-assisted treatment for patients with benign prostatic hyperplasia and its influence on serum EGF and PGE2 levels

目的研究沙巴棕软胶囊联合坦索罗辛治疗良性前列腺增生对EGF、PGE2和PSA的影响及其临床疗效。方法选取2017年9月至2018年3月汉中市人民医院泌尿外科诊治的94例良性前列腺增生(benign prostatic hyperplasia,BPH)患者为研究对象。将其随机平均分为观察组和对照组,每组47例患者。观察组患者在对照组基础上加服沙巴棕软胶囊160㎎/次,Bid;对照组患者口服盐酸坦索罗辛0.2㎎/次,Qd;两组患者均治疗12周。比较两组患者治疗有效率及治疗前后前列腺体积、残余尿量、最大尿流率(Qmax)、血清表皮生长因子(EGF)、前列腺特异抗原(PSA)、前列腺素E2(PGE2)水平和治疗过程中的不良反应。结果治疗后,观察组患者总有效率(93.6%)显著高于对照组患者(78.7%),其差异具有统计学意义(P<0.05)。治疗后,两组患者前列腺体积、残余尿量均比治疗前有所降低,观察组患者显著低于对照组患者(均P<0.05);两组患者Qmax均比治疗前有所升高,观察组患者显著高于对照组患者(P<0.05);观察组患者治疗前血清EGF、PSA、PGE2水平分别为(43.59±6.53)pg/ml、(20.21±0.71)mg/L、(3.58±0.75)ng/ml,治疗后显著降低至(21.58±7.41)pg/ml、(1.59±0.23)mg/L、(0.94±0.89)ng/ml;对照组患者治疗前血清EGF、PSA、PGE2水平为(45.37±7.51)pg/ml、(20.13±0.74)mg/L、(3.71±0.59)ng/ml,治疗后降至(29.46±10.59)pg/ml、(1.91±0.48)mg/L、(1.24±0.41)ng/ml,两组患者血清EGF、PGE2、PSA水平均比治疗前有所降低(均P<0.05),观察组患者显著低于对照组患者(均P<0.05),治疗过程中未见明显不良反应。结论沙巴棕软胶囊联合坦索罗辛治疗良前列腺增生可以缩小前列腺体积,改善尿路症状,降低血清EGF、PGE2、PSA水平,且无明显不良反应。

Objective To investigate the effect of Sabale Soft Capsules combined with tamsulosin in treating patients with benign prostatic hyperplasia(BPH) and its influence on serum EGF, PGE2 and PSA. Methods 94 elderly patients with BPH in Hanzhong People′s Hospital between September 2017 and March 2018 were randomly divided into control group and treatment group, each of 47 cases. Patients in the control group were orally administered with tamsulosin tablets, 2 mg/time, once daily. Patients in the treatment group were orally administered with Sabale Soft Capsules on the basis of the control group, 160 mg/time, twice daily. All the patients in the two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the prostatic volume, residual urine volume, Qmax, serum epidermal growth factor(EGF), prostaglandin E2(PGE2), prostate-specific antigen(PSA) levels in the two groups before and after treatment were compared. Results The therapeutic efficiency of the observation group(93.6%) was higher than that of the control group(78.7%), with statistically significant difference(P<0.05). After treatment, the prostatic volume and residual urine volume in the two groups were significantly reduced and that in the observation group was significantly lower than that in the control group(all P<0.05). Qmax in the two groups were significantly increased and that in the observation group was significantly higher than that in the control group(P<0.05). The levels of serum EGF, PGE2 and PSA in observation group were(43.59±6.53) pg/ml,(20.21±0.71) mg/L and(3.58±0.75) ng/ml respectively before treatment, which were significantly decreased to(21.58±7.41) pg/ml,(1.59±0.23) mg/L and(0.94±0.89) ng/ml accordingly after treatment(all P<0.05), and those in control group were(45.37±7.51) pg/ml,(20.13±0.74) mg/L and(3.71±0.59) ng/ml before treatment, which were significantly decreased to(29.46±10.59) pg/ml,(1.91±0.48) mg/L and(1.24±0.41) ng/ml after treatment(all P<0.05). After treatment, the serum EGF, PGE2, PSA levels in the two groups were significantly decreased, and those in the observation group were significantly lower than those in the control group(all P<0.05). No obvious adverse reactions were observed during the treatment. Conclusions Sabale Soft Capsules combined with tamsulosin can reduce prostate volume, improve urinary tract symptoms and reduce serum EGF, PGE2 and PSA levels of patients with BPH without obvious adverse reactions.